Antisense inhibition of phospholipase A2: A new approach for already tested therapeutic targets for the treatment of sepsis

Critical Care Medicine

Volumn 40, Issue 7, 2012, Pages 2250-2251

  Touqui, Lhousseine ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Antisense; phospholipase A2; sepsis

Indexed keywords

ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 GROUP II;

ANTISENSE THERAPY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SPECIFICITY; EDITORIAL; ENZYME INHIBITION; GENE EXPRESSION REGULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS;

ANIMALS; GROUP IV PHOSPHOLIPASES A2; MALE; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOLIPASES A2, SECRETORY; SEPSIS;

EID: 84862748328     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31825151bd     Document Type: Editorial

References (15)

1. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005; 365:63-78
2. Touqui L, Alaoui-El-Azher M: Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr Mol Med 2001; 1:739-754 (Pubitemid 33772947)
3. Shapiro NI, Wolfe RE: Moore RB, et al: Mortality in Emergency Department Sepsis (MEDS) score: A prospectively derived and validated clinical prediction rule. Crit Care Med 2003; 31:670-675 (Pubitemid 36379566)
4. Marshall JC: Sepsis: Rethinking the approach to clinical research. J Leukoc Biol 2008; 83:471-482 (Pubitemid 351966853)
5. Abraham E, Naum C, Bandi V, et al: Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 2003; 31:718-728 (Pubitemid 36379574)
6. Bernard GR, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912-918 (Pubitemid 27137191)
7. Opal S, Laterre PF, Abraham E, et al; Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32:332-341 (Pubitemid 38234108)
8. For Sepsis, the drugs don't work. Lancet Infect Dis 2012; 12:89
9. Liu M-S, Liu C-H, Wu G, et al: Antisense inhibition of secretory and cytosolic phospholipase A2 reduces the mortality in rats with sepsis. Crit Care Med 2012; 40:2132-2140
10. Phillips MI, Galli SM, Mehta JL: The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease. Drugs 2000; 60:239-248
11. Attalah HL, Wu Y, Alaoui-El-Azher M, et al: Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury. Eur Respir J 2003; 21:1040-1045 (Pubitemid 36675623)
12. Hamaguchi K, Kuwata H, Yoshihara K, et al: Induction of distinct sets of secretory phospholipase A(2) in rodents during inflammation. Biochim Biophys Acta 2003; 1635: 37-47 (Pubitemid 37464994)
13. Nakos G, Kitsiouli E, Hatzidaki E, et al: Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med 2005; 33:772-779
14. Bannenberg G, Serhan CN: Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta 2010; 1801:1260-1273
15. Wu Y, Raymond B, Goossens PL, et al: Type-IIA secreted phospholipase A2 is an endogenous antibiotic-like protein of the host. Biochimie 2010; 92:583-587